The phase 2 KARDIA-2 study showed that a single subcutaneous dose of zilebesiran, an investigational RNA interference agent, reduced systolic blood pressure when added to other antihypertensive medications. The drug was generally safe, well-tolerated, and showed promise as part of combination therapy, offering a potential option for patients with hypertension. Data from the study also indicated that injectable therapies, like zilebesiran, could be an effective alternative for patients who struggle with adherence to oral medications. Further analysis is needed to understand the efficacy and potential barriers to acceptance of injectable antihypertensive therapies.
Source link
Twice-yearly injectable antihypertensive drug lowers BP at 6 months: KARDIA-2
